- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00114959
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
A Phase II Open-Label Study of the Intravenous Administration of Homoharringtonine (CGX-635) Combined With the Oral Administration of Gleevec in the Treatment of Patients With Chronic Myeloid Leukemia (CML) in Chronic, Accelerated, and Blast Phase
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Univ. of Texas M.D. Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients 16 years or older
- Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) in either chronic, accelerated or blast phase
- Patients with chronic phase CML will be either refractory (failed to achieve hematologic or cytogenetic response) or resistant (responded initially but subsequently lost hematologic or cytogenetic response) to prior imatinib mesylate therapy. Failure to achieve cytogenetic response is defined as follows: no cytogenetic response after 3 months of therapy with imatinib mesylate, no major cytogenetic response at 12 months of therapy, loss of complete cytogenetic response documented twice, or loss of major cytogenetic response at least once.
- Patients with accelerated or blast phase may be newly diagnosed and previously untreated or if previously treated with imatinib mesylate, will be refractory or resistant to this agent or have failed to achieve at least a complete hematologic or cytogenetic response to treatment, as previously defined.
- Patients in accelerated phase will meet one or more of the following criteria: greater than or equal to 15% through less than 30% blasts in peripheral blood or bone marrow, greater than or equal to 30% blasts + promyelocytes in peripheral blood or bone marrow, greater than or equal to 20% basophils in peripheral blood, platelet count less than 100*10^9/L unrelated to therapy or clonal evolution.
- CML in blast phase will be defined as greater than or equal to 30% blasts in the bone marrow or presence of extramedullary disease
- Patients must have completed all previous anti-leukemic therapy for at least 2 weeks, except as noted, and have fully recovered from side effects of a previous therapy, unless disease progression necessitates early therapy. Patients may receive leukapheresis, hydroxyurea and anagrelide for up to 24 hours prior to start of study treatment. Patients receiving imatinib mesylate may continue to receive it uninterrupted, except for a 3-day window at treatment cycle 1.
- Bilirubin less than or equal to 2 times the upper limit of normal (ULN); alanine aminotransferase (ALT) less than or equal to 3 times ULN; creatinine less than or equal to 1.5 times ULN
- Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2
- Be able to comply with the requirements of the entire study
- Be able and willing to provide written informed consent prior to any study related procedure
- Patients and their partners must use an effective contraceptive during the study dosing period. The following are considered effective contraceptives: oral contraceptive pill, condom, diaphragm plus spermicide, abstinence, patient or partner surgically sterile, patient or partner more than 2 years post-menopausal, or injectable or implantable agent/device.
Exclusion Criteria:
- New York Heart Association (NYHA) Class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia and requiring therapy, uncontrolled hypertension or congestive heart failure
- Myocardial infarction in the previous 12 weeks
- Other intercurrent illness which would preclude study conduct and assessment, including but not limited to another active malignancy, uncontrolled and active infection, positive human immunodeficiency virus (HIV) or human T-cell lymphotropic virus (HTLV) I/II status
- Pregnant or lactating
- Any medical or psychiatric condition which may compromise the ability to give written informed consent or to comply with the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Homoharringtonine + Imatinib Mesylate
Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m^2 by continuous 24-hour intravenous infusion daily on Days 1-5 of each 4 week treatment cycle, and imatinib mesylate (Gleevec) by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML.
|
Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m^2 by continuous 24-hour intravenous (IV) infusion daily on Days 1-5 of each 4 week treatment cycle. Participants who do not achieve a meaningful hematologic or cytogenetic response by the end of the fourth cycle are discontinued from the study. Otherwise, participants may continue additional cycles of this combined treatment for a maximum of 12 cycles. Participants who achieved a molecular or cytogenetic response, or a complete hematologic remission (CHR), could undergo subsequent cycles with a maintenance schedule of homoharringtonine 2.5 mg/m^2 by continuous 24-hour IV infusion daily for 2 days every 4 weeks. Dose escalations in subsequent cycles were allowed by one day at a time if the participant was unable to maintain CHR in the maintenance schedule.
Other Names:
Taken by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML.
For the first cycle of therapy only, imatinib was started on Day 4 of homoharringtonine treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Participants With Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (CML) Who Achieve a Meaningful Response
Time Frame: up to month 4
|
Participants in accelerated or blast phase who converted to at least CML-chronic phase. CML in accelerated phase meets one or more of the following criteria: >=15% - <30% blasts in peripheral blood or bone marrow, >=30% blasts + promyelocytes in peripheral blood or bone marrow, >=20% basophils in peripheral blood; platelet count <100*10^9/L unrelated to therapy or clonal evolution. CML in blast phase have >=30% blasts in the bone marrow or presence of extramedullary disease. Meaningful responses include (in descending order of health)
|
up to month 4
|
Proportion of Participants With Chronic Phase Chronic Myeloid Leukemia (CML) Who Achieve a Meaningful Response
Time Frame: up to month 4
|
Participants who are not in complete hematologic remission (CHR) at study start must achieve at least a CHR, and participants who are in CHR at onset must demonstrate an improvement in their cytogenetics. A Complete Hematologic Remission (CHR) involves normalization of the bone marrow (less than 5% blasts) and peripheral blood with white blood cells < 10*10^9/L, absolute neutrophil count >=1*10^9/L, platelets >=100*10^9/L and no peripheral blasts, promyelocytes or myelocytes. This is in addition to disappearance of all signs and symptoms of the disease. |
up to month 4
|
Number of Participants With Adverse Experiences (AEs)
Time Frame: up to 3 years
|
Summary of participants who had adverse events (AEs), who discontinued treatment due to the AE, who had serious adverse events (SAEs), and who had SAEs that were related to treatments. A serious adverse event is one that at any dose of the study drug or at any time during the period of observation:
The Investigator assessed each AE for potential causal relationship between the event and study drug. An investigator assessment of possibly, probably or unknown relation is considered related. |
up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants With Complete Hematologic Remission Suppression of the Philadelphia Chromosome
Time Frame: up to month 4
|
Complete hematologic remission was further classified according to the suppression of the Philadelphia chromosome (Ph) as: No cytogenetic response - Ph positive 100% Minimal cytogenetic response - Ph positive 35-90% Partial cytogenetic response - Ph positive 1-34% Complete cytogenetic response - Ph positive 0% |
up to month 4
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Adam R Craig, M.D., PhD, ChemGenex Pharmaceuticals
- Principal Investigator: Jorge Cortes, M.D., Univ. of TX M.D. Anderson Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Leukemia
- Chronic Myeloid Leukemia
- Homoharringtonine
- Chronic Phase
- Leukemia, Myeloid, Chronic
- Myeloid Leukemia
- Blast Phase
- ChemGenex Pharmaceuticals, Ltd
- ChemGenex Pharmaceuticals
- ChemGenex
- Myeloid Leukemia, Chronic
- Accelerated Phase
- Myeloid, Leukemia, Chronic, Accelerated Phase
- Myeloid, Leukemia, Chronic
- Leukemia, Myeloid, Chronic-Phase
- Leukemia, Myeloid, Chronic Phase
- Leukemia, Myeloid, Accelerated-Phase
- Myeloid, Leukemia, Chronic, Chronic Phase
- Leukemia, Myeloid, Accelerated Phase
- Omacetaxine
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Neoplastic Processes
- Cell Transformation, Neoplastic
- Carcinogenesis
- Leukemia
- Leukemia, Myeloid
- Chronic Disease
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Blast Crisis
- Leukemia, Myeloid, Accelerated Phase
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Protein Kinase Inhibitors
- Protein Synthesis Inhibitors
- Imatinib Mesylate
- Homoharringtonine
Other Study ID Numbers
- CGX-635-CML-201
- MDACC protocol #2005-0067 (Other Identifier: M.D. Anderson Cancer Center)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myeloid Leukemia, Chronic, Chronic-Phase
-
Asan Medical CenterTerminatedLeukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated PhaseKorea, Republic of
-
Newcastle UniversityBristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaboratorsCompletedMyeloid Leukemia, Chronic, Chronic PhaseUnited Kingdom
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myelogenous Leukemia - Chronic PhaseChina
-
Fundacion Espanola para la Curacion de la Leucemia...Pfizer; Roche Farma, S.ATerminatedChronic Phase-Chronic Myeloid LeukemiaSpain
-
TakedaActive, not recruitingMyeloid Leukemia, Chronic, Chronic PhaseUnited States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte Corporation; H. Jean Khoury Cure CML ConsortiumRecruitingChronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
Korean Society of HematologyNot yet recruitingChronic Myeloid Leukemia, Chronic Phase
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.RecruitingCML, Chronic Phase | CML, Accelerated PhaseChina
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveUnited States, Canada, Australia, Puerto Rico
Clinical Trials on Homoharringtonine
-
National Cancer Institute (NCI)WithdrawnLeukemiaUnited States
-
Air Force Military Medical University, ChinaThe Second Hospital of Hebei Medical University; Qilu Hospital of Shandong... and other collaboratorsRecruiting
-
The University of Hong KongCompletedAML | FLT3-ITD MutationHong Kong
-
The University of Hong KongUnknownAML | FLT3-ITD MutationHong Kong
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
The First Affiliated Hospital with Nanjing Medical...RecruitingSecondary Acute Myeloid LeukemiaChina
-
First Affiliated Hospital of Zhejiang UniversityRecruitingAcute Myeloid Leukemia, AdultChina
-
Nanfang Hospital of Southern Medical UniversityThe Affiliated Hospital of Qingdao University; Sun Yat-Sen Memorial Hospital... and other collaboratorsRecruitingVenetoclax Combined With Azacitidine Plus Homoharringtonine | Venetoclax Combined With AzacitidineChina
-
ChemGenex PharmaceuticalsCompleted
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic LeukemiaUnited States